We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.
- Recent SANA Stock Price: $4.09
- Yearly Gain for SANA stock: -7.13%
- Market Cap for SANA stock: $796.42M
- P/E Ratio for SANA stock: -2.807
Will SANA's stock price go up? Is there an accurate SANA stock forecast available?
TipRanks.com reports that Sana Biotechnology currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $8.00. The target pricing ranges from a high SANA forecast of $8 down to a low forecast of $8. Sana Biotechnology (SANA)’s last closing stock price was $4.09 which would put the average price target at 95.60% upside.
In addition, TradingView issued a Neutral rating for SANA stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SANA stock.
Other analysts covering SANA include:
- Reni Benjamin of JMP Securities issued a Buy rating with the price target of $8 on 18 hours ago
- Samantha Semenkow of Citi issued a Buy rating with the price target of $8 on 1 day ago
If you are wondering if SANA is a good stock to buy, here are 3rd party ratings for SANA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 19% (47 out of 251)
What is the sentiment on the street regarding Sana Biotechnology? (Current ratings compiled by TipRanks.com)
- News Sentiment for SANA stock: Very Bullish
- Blogger Consensus for SANA stock: Bullish
- Media Buzz for SANA stock: Low
- Insider Signal for SANA stock: ―
- Investor Sentiment for SANA stock: Very Negative
- Hedge Fund signal for SANA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on SANA stock including scouring the social networks like SANA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SANA stock chart >>
Summary: Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.
- Recent MRUS Stock Price: $23.59
- Yearly Gain for MRUS stock: 76.97%
- Market Cap for MRUS stock: $1.45B
- P/E Ratio for MRUS stock: -6.759
Will MRUS's stock price go up? Is there an accurate MRUS stock forecast available?
TipRanks.com reports that Merus currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $45.60. The target pricing ranges from a high MRUS forecast of $49 down to a low forecast of $42. Merus (MRUS)’s last closing stock price was $23.59 which would put the average price target at 85.12% upside.
In addition, TradingView issued a Neutral rating for MRUS stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MRUS stock.
Other analysts covering MRUS include:
- Ami Fadia of Needham issued a Buy rating with the price target of $42 on 18 hours ago
- William Maughan of Canaccord Genuity issued a Buy rating with the price target of $45 on 1 day ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $48 on 6 days ago
- Etzer Darout of BMO Capital issued a Buy rating with the price target of $49 on 1 week ago
If you are wondering if MRUS is a good stock to buy, here are 3rd party ratings for MRUS stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 19% (47 out of 251)
What is the sentiment on the street regarding Merus? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRUS stock: Very Bullish
- Blogger Consensus for MRUS stock: Neutral
- Media Buzz for MRUS stock: Medium
- Insider Signal for MRUS stock: ―
- Investor Sentiment for MRUS stock: Very Positive
- Hedge Fund signal for MRUS stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on MRUS stock including scouring the social networks like MRUS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRUS stock chart >>
Summary: Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
- Recent NVO Stock Price: $100.92
- Yearly Gain for NVO stock: 59.44%
- Market Cap for NVO stock: $456.49B
- P/E Ratio for NVO stock: 41.604
Will NVO's stock price go up? Is there an accurate NVO stock forecast available?
TipRanks.com reports that Novo Nordisk currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $114.25. The target pricing ranges from a high NVO forecast of $120 down to a low forecast of $107. Novo Nordisk (NVO)’s last closing stock price was $100.92 which would put the average price target at 15.61% upside.
In addition, TradingView issued a Neutral rating for NVO stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on NVO stock.
Other analysts covering NVO include:
- Jasper Hellweg of Argus Research issued a Buy rating with the price target of $115 on 3 days ago
- Louise Chen of Cantor Fitzgerald issued a Buy rating with the price target of $120 on 3 days ago
- Sachin Jain of Bank of America Securities issued a Buy rating with the price target of $107 on 3 months ago
If you are wondering if NVO is a good stock to buy, here are 3rd party ratings for NVO stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Strong Buy, Top 37% (93 out of 251)
What is the sentiment on the street regarding Novo Nordisk? (Current ratings compiled by TipRanks.com)
- News Sentiment for NVO stock: Very Bullish
- Blogger Consensus for NVO stock: Bullish
- Media Buzz for NVO stock: Low
- Insider Signal for NVO stock: ―
- Investor Sentiment for NVO stock: Very Positive
- Hedge Fund signal for NVO stock: Neutral
The stock market is extremely volatile, and you need to do your own research on NVO stock including scouring the social networks like NVO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NVO stock chart >>
Summary: Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
- Recent EW Stock Price: $69.18
- Yearly Gain for EW stock: -7.43%
- Market Cap for EW stock: $41.46B
- P/E Ratio for EW stock: 29.231
Will EW's stock price go up? Is there an accurate EW stock forecast available?
TipRanks.com reports that Edwards Lifesciences currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $74.25. The target pricing ranges from a high EW forecast of $80 down to a low forecast of $57. Edwards Lifesciences (EW)’s last closing stock price was $69.18 which would put the average price target at 13.31% upside.
In addition, TradingView issued a buy rating for EW stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on EW stock.
Other analysts covering EW include:
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $80 on 18 hours ago
- Josh Jennings of TD Cowen issued a Buy rating with the price target of $80 on 3 days ago
- Michael Polark of Wolfe Research issued a Sell rating with the price target of $57 on 1 week ago
If you are wondering if EW is a good stock to buy, here are 3rd party ratings for EW stock:
- TipRanks.com: Moderate Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 29% (74 out of 251)
What is the sentiment on the street regarding Edwards Lifesciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for EW stock: Bearish
- Blogger Consensus for EW stock: Bullish
- Media Buzz for EW stock: High
- Insider Signal for EW stock: ―
- Investor Sentiment for EW stock: Positive
- Hedge Fund signal for EW stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on EW stock including scouring the social networks like EW StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for EW stock chart >>
Summary: AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
- Recent ATRC Stock Price: $36.48
- Yearly Gain for ATRC stock: -16.22%
- Market Cap for ATRC stock: $1.73B
- P/E Ratio for ATRC stock: -68.1
Will ATRC's stock price go up? Is there an accurate ATRC stock forecast available?
TipRanks.com reports that Atricure currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $59.75. The target pricing ranges from a high ATRC forecast of $65 down to a low forecast of $49. Atricure (ATRC)’s last closing stock price was $36.48 which would put the average price target at 50.77% upside.
In addition, TradingView issued a Sell rating for ATRC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on ATRC stock.
Other analysts covering ATRC include:
- Marie Thibault of BTIG issued a Buy rating with the price target of $65 on 3 days ago
- Daniel Stauder of JMP Securities issued a Buy rating with the price target of $60 on 5 days ago
- Michael Matson of Needham issued a Buy rating with the price target of $49 on 6 days ago
If you are wondering if ATRC is a good stock to buy, here are 3rd party ratings for ATRC stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Bottom 43% (144 out of 251)
What is the sentiment on the street regarding Atricure? (Current ratings compiled by TipRanks.com)
- News Sentiment for ATRC stock: Very Bullish
- Blogger Consensus for ATRC stock: Bullish
- Media Buzz for ATRC stock: High
- Insider Signal for ATRC stock: ―
- Investor Sentiment for ATRC stock: ―
- Hedge Fund signal for ATRC stock: Negative
The stock market is extremely volatile, and you need to do your own research on ATRC stock including scouring the social networks like ATRC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ATRC stock chart >>
Summary: Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.
- Recent ALT Stock Price: $4.63
- Yearly Gain for ALT stock: -67.72%
- Market Cap for ALT stock: $191.81M
- P/E Ratio for ALT stock: -2.324
Will ALT's stock price go up? Is there an accurate ALT stock forecast available?
TipRanks.com reports that Altimmune currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.00. The target pricing ranges from a high ALT forecast of $8 down to a low forecast of $15. Altimmune (ALT)’s last closing stock price was $4.63 which would put the average price target at 245.57% upside.
In addition, TradingView issued a Strong Buy rating for ALT stock over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALT stock.
Other analysts covering ALT include:
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $25 on 18 hours ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $8 on 3 days ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $15 on 3 days ago
- Jonathan Wolleben of JMP Securities issued a Buy rating with the price target of $16 on 4 days ago
If you are wondering if ALT is a good stock to buy, here are 3rd party ratings for ALT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 28% (70 out of 251)
What is the sentiment on the street regarding Altimmune? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALT stock: Very Bullish
- Blogger Consensus for ALT stock: Bullish
- Media Buzz for ALT stock: Very High
- Insider Signal for ALT stock: ―
- Investor Sentiment for ALT stock: Very Positive
- Hedge Fund signal for ALT stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ALT stock including scouring the social networks like ALT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
